Bibliographic information

GuidelineClinical management of COVID-19: living guideline, 23 June 2022.
Year of Publication2022
Issuing InstitutionWHO

Recommendation

Maintained

The World Health Organization (WHO) recommends, in hospitalized patients with COVID-19, without an established indication for higher dose anticoagulation, we suggest administering standard thromboprophylaxis dosing of anticoagulation rather than therapeutic or intermediate dosing.

Recommended in favor

Conditional

Notes and Remarks

Practical Info Therapeutic dosing of anticoagulation refers to the dose used for treatment of acute venous thromboembolism; intermediate dosing is commonly interpreted as twice the standard thromboprophylaxis dose. The GDG made a conditional recommendation in favour of standard thromboprophylaxis dosing of anticoagulation in patients with COVID-19 who do not have an established indication for higher dose anticoagulation. Patients on standard thromboprophylaxis dosing of anticoagulation do not require monitoring, except for platelet count monitoring after 5–7 days if unfractionated heparin is used. Dosing should be adjusted according to body weight/BMI and renal function according to local protocols. For example, if renal failure is present, patient should receive unfractionated heparin or reduced dose of low molecular weight heparin. Suggested dosing of standard thromboprophylaxis is as follows: Enoxaparin 40 mg by subcutaneous injection every 24h:

  • Prophylactic dosages (non-weight adjusted) in low body weight (women < 45 kg, men < 57 kg) may lead to a higher risk of bleeding. Careful clinical observation is advised.
  • If BMI > 40 kg/m2 or weight > 120 kg: enoxaparin 40 mg by subcutaneous injection every 12h. Unfractionated heparin (UFH) 5000 units by subcutaneous injection every 8 or 12h:
  • If BMI > 40 kg/m2 or weight > 120 kg: 7500 units q12h or 5000 units every 8h. Tinzaparin 4500 units/day if BMI < 40 kg/m2 or weight < 120 kg; 9000 units/day if BMI > 40 kg/m2 or weight > 120 kg.
  • Dalteparin 5000 units/day BMI < 40 kg/m2 or weight < 120 kg; 5000 units every 12 h if BMI > 40 kg/m2 or weight > 120 kg.
  • Fondaparinux 2.5 mg by subcutaneous injection every 24h. Exoxaparin and unfractionated heparin are both on the WHO Model List of Essential Medicines; enoxaparin has the advantage of daily dosing. The suggested duration of standard thromboprophylaxis is until hospital discharge. If therapeutic dosing is prescribed, clinicians should be aware of the increased risk of bleeding, including major bleeding requiring transfusion (e.g. gastrointestinal) or clinically significant bleeding even if transfusion is not required (e.g. intracranial). These increased risks may also occur with intermediate dosing of anticoagulants, especially in the presence of other risk factors for bleeding. Heparin-induced thrombocytopenia associated with thrombosis is also a risk of unfractionated heparin and, less commonly, low molecular weight heparin. Potential agents for therapeutic and intermediate intensity anticoagulation include low molecular weight heparin, unfractionated heparin, direct oral anticoagulants, or fondaparinux. Factors influencing the choice of agent include availability of laboratory monitoring (needed for unfractionated heparin), requirement for rapid reversibility (favours unfractionated heparin), presence of severe renal dysfunction (favours unfractionated heparin), interaction with other drugs used to treat COVID-19 (especially direct oral anticoagulants), convenience (least with unfractionated heparin, most with direct oral anticoagulants), and suspicion of heparininduced thrombocytopenia (favours fondaparinux or direct oral anticoagulants). For therapeutic or intermediate intensity anticoagulation, patients should have baseline creatinine, platelet count, prothrombin time or international normalized ratio, and partial thromboplastin time. Patients on therapeutic dosing of unfractionated heparin require monitoring of partial thromboplastin time or anti-factor Xa levels and ideally platelet count. Patients on warfarin require monitoring of international normalized ratio.

Important considerations Unfractionated heparin sodium and low molecular weight heparins such as enoxaparin are relatively inexpensive and are listed on the WHO Model List of Essential Medicines; but availability is variable. Shortages may reduce the availability of low molecular weight heparins in some settings. In low-resource settings, management of bleeding complications in patients receiving anticoagulant dosing higher than that used for standard thromboprophylaxis may be challenging due to limited coagulation testing and transfusion capacity.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

COVID-19 clinical management: living guidance, 25 January 2021.

Year2021
InstitutionWorld Health Organization
Guideline

Living guidance for clinical management of COVID-19: living guidance, 23 November 2021.

Year2021
InstitutionWorld Health Organization
Guideline

Clinical management of COVID-19: living guideline, 15 September 2022.

Year2022
InstitutionWHO
Guideline

Clinical management of COVID-19: living guideline, 13 January 2023.

Year2023
InstitutionWHO
Guideline

Clinical management of COVID-19: living guideline, 18 August 2023

Year2023
InstitutionWHO